IL6 and COVID-19: In apparent accordance with its hypothesized effects, pentoxifylline frequently improved inflammatory markers such as CRP and IL-6 in some studies but not uniformly; however, the impact of PTX on mortality rates among COVID-19 patients remains inconclusive, with no significant reduction observed in the pooled analysis within the relatively short timeframes of the studies.